The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
I don’t believe the directors can buy at the moment, wouldn’t this be a closed period given the interim financial results and trading statement are due to be issued in less than 2 weeks. Perhaps, I am wrong and happy to be corrected.
But yes, investments by the directors would give a very strong signal to shareholders and the market.
PCS1954 and Sadoldgit - excellent well balanced posts that provide a constructive way forward. I am fully supportive on this. Though, I do feel the BOD need to shoulder some of the pain, either they dig deep or salary deferrals until appropriate finance / investment is place to pursue the long term objectives of the company. All resources should be focused on full completion of 1801.
More than happy to provide support to reach the end goal!
Smart_Inv - I agree re having faith. I have been a long term shareholder from the dark days where the share price sat at 0.20p (old money) and remember all the fundraising to help the Company progress the compounds. There have been many ups and downs and feel there is still a few hurdles to reach the end goal.
It is very very dark at the moment. I’m trying my hardest to keep the faith and in that the board of directors can put in place appropriate funding to at least allow the completion of Phase 1a. This is a very critical inflexion point for the company and should
Open many doors; on-licence, investment or maybe a major taking a stake. This should allow the progression of 1B and pushing 1802 into clinical trials, 1802 I believe is the more valuable of the TYK2/JAK1 inhibitors.
Good luck to all investors in the hope of a construction resolution to the current situation.
Potnak I thought exactly the same with primary bid - I remember those days only too well. This would provide the opportunity to solve immediate funding issues and would allow breathing space to explore longer term funding to proceed with Phase 1B.
It seems from the same RNS on 3rd August 2023 re the RiverFort model that RiverFort will also benefit if Sareum undertake any open offer of shares, noted below.
“Should the Company undertake a share placing during each relevant Warrant Term, the Warrant Price will be reset to the placing price if the resultant Warrant Price would be lower.”
I noticed this paragraph from the RNS released on 3rd August 2023 when the RiverFort model was announced.
“In the event that the Company is unable to draw down the majority of the additional £2.4 million potentially available under the Facility as and when expected, the Company will require alternative funding to complete the Phase 1b clinical developments activities being progressed and to provide working capital.”
You would like to think there is some sort of Plan B as a contingency as the risk was always there with the horrendous RiverFort funding model.
One thing I think everyone should take note on is the following-
“However, if the MHRA requires further information then a ‘Grounds for Non- Acceptance’ (GNA) letter is issued. This should not be viewed as the rejection of a study, rather a request for more information. If further information is requested, companies have 14 days (unless permission is sought from the MHRA to increase this timeline) to respond or their trial would be deemed not–approved.” - source: https://www.celerion.com/wp-content/uploads/2010/08/Managing_Clinical_Trial_Application.pdf
The CTA as far as we know has not been rejected, further information has been requested.
We hope the necessary information can be provided to allow the MHRA to proceed with granting the CTA.
I’ve been a reader of this board for years and never in all the years I have been invested in Sareum, never has this board had such vile nasty comments thrown at various posters. There have been up and downs along the way, I remember the days of the share price wallowing below 1p, this has just descended into a complete farce.
Can we please get back to posting informative posts that allows various posters to form an opinion on the Company and its product development, both positive and negative respectfully. The childish tit for tat has just become a joke now.
Apologies for this post. However, this just needed to be said and I very much welcome a return to normality away from the vitriol spouted here over the past few weeks.
Good luck to All investors in hopefully better times ahead.
Evening all.
I’ve been a Sareum shareholder since the days of the 10 out of 10 mice. Honestly, did not think I would still be here after all this time. I read the board frequently but have never felt the need to post. I appreciate the level of detail and analysis various posters have to offer, this helps to reinforce my faith in the Company.
I just want to share some findings, it might mean nothing. From the investor meet presentation back in February to discuss the share consolidation, at 52:54 Tim does state the Toxicology report is a very complex document and has to be produced to Good Laboratory Practices (GLP).
I could be barking up the wrong tree but just felt I would share my findings.